Mayo Clinic and Thermo Fisher Scientific launch Precure, LLC to uncover early disease signals

This initiative leverages advanced AI and large-scale data analytics to analyze complex molecular and clinical data over time. Precure aims to accelerate drug development, improve understanding of disease progression, and foster innovations in diagnostics and therapeutics across various diseases such as cancer and neurological disorders.

Mayo Clinic and Thermo Fisher Scientific have partnered to launch Precure, LLC to help transform how the life sciences community understands the biological changes that occur as people move from health toward disease. 

Precure, LLC will create one of the world’s leading biomedical datasets through one of the largest human multi-omics data-generation efforts, integrating proteomic, genomic and longitudinal clinical data to help researchers identify early biological signals of disease and provide a foundation for new discoveries in disease biology, diagnostics and therapeutics. 

Many diseases begin developing biologically years before symptoms lead to a clinical diagnosis. By connecting molecular and clinical data over time, Precure, LLC has the potential to help researchers better understand these early changes, accelerate drug development and create new opportunities for earlier diagnosis, intervention and more personalized care across a wide range of diseases, such as cancer, cardiometabolic disease, neurological disorders and immune-mediated disease. 

Precure, LLC will bring together molecular data generated from one million biospecimens, linked with longitudinal clinical information collected over several years, integrating genomic and proteomic information with Mayo Clinic’s clinical data and expertise in a highly standardized setting. Advanced AI and large-scale data-analytics will be integral to identifying patterns within these complex datasets and translating them into actionable insights. Mayo Clinic will serve as the majority owner of Precure, LLC. Thermo Fisher joins the partnership as a minority owner. 

Together, the organizations contribute complementary expertise designed to generate the molecular and clinical data needed to accelerate discovery and translate new insights into advancements in patient care.

Precure, LLC complements Precure Research, Mayo Clinic’s investigator-led scientific effort to understand the biological changes that occur as people move from health toward disease. Precure Research advances the science of identifying and understanding early disease signals, while Precure, LLC provides the scale, infrastructure and collaborations needed to generate population-scale molecular data and help translate discoveries into new diagnostics, therapeutics and other healthcare solutions. Mayo Clinic provides the pathway to validate discoveries and ultimately brings meaningful advances into patient care. 

Visit Thermo Fisher for more information

About the Author

 LABline
Sign up for our eNewsletters
Get the latest news and updates